Table 5.
Use of other haemostatic agents throughout the study
| Name of coagulation factor | Participants receiving ≥ 1 dose, n (%) | Total doses given, n | Purpose of use | Dose (IU/kg), median (range) | |
|---|---|---|---|---|---|
| Haemostasis, n (%) | Other, n (%) | ||||
| Overall | 74 (69.8) | 584 | 284 (48.6) | 300 (51.4) | NA |
| Rurioctocog alfa pegol | 23 (21.7) | 169 | 126 (74.6) | 43 (25.4) | 28.78 (19.4–80.0) |
| Rurioctocog alfa | 18 (17.0) | 86 | 27 (31.4) | 59 (68.6) | 37.88 (15.0–146.2) |
| Efraloctocog alfa | 17 (16.0) | 163 | 40 (24.5) | 123 (75.5) | 51.90 (26.6–68.3) |
| Octocog beta | 8 (7.5) | 31 | 7 (22.6) | 24 (77.4) | 25.03 (20.7–62.1) |
| Lonoctocog alfa | 5 (4.7) | 9 | 4 (44.4) | 5 (55.6) | 34.40 (19.3–52.1) |
| Turoctocog alfa | 5 (4.7) | 83 | 47 (56.6) | 36 (43.4) | 28.90 (20.2–120.5) |
| Cross eight | 2 (1.9) | 8 | 3 (37.5) | 5 (62.5) | 17.24 (16.6–33.2) |
| Octocog alfa | 2 (1.9) | 4 | 3 (75.0) | 1 (25.0) | 30.76 (29.0–31.3) |
| Tranexamic acid | 1 (0.9) | 27 | 27 (100.0) | 0 (0.0) | NA |
| Damoctocog alfa pegol | 1 (0.9) | 4 | 0 (0.0) | 4 (100.0) | 38.36 (38.4–38.4) |
IU international unit, NA not available